Biogen’s ALS Drug Gets Partial Backing From FDA Panel

A Biogen Inc. drug that targets a rare form of ALS got partial support from a panel of US Food and Drug Administration advisers Wednesday, paving the way for a possible accelerated approval.

If it’s approved, the medication, tofersen, would be the first drug targeting a specific genetic cause of the incurable paralysis disease to get the regulatory green light.